ClinicalTrials.gg
RecruitingNCT06576479Updated Dec 18, 2024

Effect of a Specialized Oral Supplement on Nutritional Status and Quality of Life in Non-dialysis CKD

An interventional study of Nutritious Shake and Nutritional counseling in Chronic Kidney Diseases and Protein-Energy Malnutrition, sponsored by NIN Institute. Recruiting at 1 site in Mexico. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-12-18.

Sponsored by NIN Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Registered 6 years 1 month after the study started (first participant enrolled Jul 2018, registered Aug 2024).
  • Started Jul 2018; still recruiting 8 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies in Renal Insufficiency, Chronic with a site in Mexico — 19 open to participants now, 31 under way, 14 of them phase 3. Renal Insufficiency, Chronic · Mexico.

Planned enrollment
65th of 77
50 · median 341
Started
2018
with 7 others
No phase
17 of 83
5 open now
Primary completion
2025-02
later than 1 of 30 live
Registered
63rd of 83
by date

Among the 83 studies in Renal Insufficiency, Chronic with a site in Mexico, this one is the 65th largest by planned enrollment of the 77 interventional ones that give a count, is one of 8 that started in 2018, is one of 17 with no phase, reaches primary completion later than 1 of the 30 other live ones, and was the 63rd registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

19 of the 83 studies in Renal Insufficiency, Chronic with a site in Mexico are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Renal Insufficiency, Chronic with a site in Mexico, or all of them as a file.
02

Study summary

Patients whit chronic kidney disease (CKD) there is a high prevalence of nutritional disorders and negative changes in body composition, which is strongly associated with an increased risk of morbidity and mortality.

Read the detailed description

Epidemiological studies have reported that between 30 and 50% of patients with kidney disease show signs of malnutrition and that specifically in patient with CKD in stages 4-5 without replacement therapy, the prevalence of protein energy wasting (PEW) can be up to 45%.

Many factors influence the development of PEW, however, one main factor is insufficient intake of energy and macronutrients. The main obstacle that prevents the patient from meeting their nutritional requirements is the presence of gastrointestinal symptoms. In addition to this, dietary restrictions, lack of adherence to eating plans and the presence of digestive and psychological abnormalities of the patient, contribute directly to the patient directly contribute to insufficient energy and protein intake. Therefore, there is a need for evidence-based nutritional treatment strategies that facilitate the patient's achievement of their nutritional requirements and maintain or improve their nutritional supplements in patients with CKD has been shown to be a good treatment strategy.

Specifically in patients with CKD without replacement therapy, it has been observed that the use of specialized nutritional supplements can contribute to increasing their energy, fat, and fiber intake, while at the same time achieving a decrease in protein intake without causing any change in serum minerals or electrolytes.

This project will provide practical information for the validation of the therapeutic effect of a new specialized food supplement on the nutritional status and quality of life in patients with CKD without replacement therapy, which will be useful both for health professionals and for the patients themselves.

MAIN OBJETIVE:

To assess the effect and safety of the use of a specialized food supplement on the nutritional status and quality of life of patients with CKD and PEW without replacement therapy.

STUDIO DESING:

Randomized, blinded clinical trial with an intervention period of 4 months.

PROCESS:

  1. Identify those patients who are candidates to participate in the clinical trial.
  2. Review the inclusion and exclusion criteria.
  3. Invite identified patients to participate in the clinical trial.

Pre - Nutritional wash out appointment - nutritionist

  1. Evaluate inclusion criteria.
  2. Review and sign the informed consent.
  3. Perform evaluation to indicate a personalized meal plan.
  4. Deliver a meal plan.
  5. Schedule in 30 days for your next nutritional appointment.

0 - Full Assessment Nutritional Appointment - Nutritionist

  1. Evaluate adherence to the meal plan (percentage of adequacy of energy and protein consumption from 70% to 130%).
  2. Assign an intervention group randomly (sealed envelope).
  3. Perform an evaluation of nutritional status, quality of life and body composition.

    Offer nutritional treatment according to the assigned intervention group.

  4. Schedule an immediate appointment for laboratory tests of blood and urine.
  5. Schedule in 30 days for your next nutritional appointment.

month 1 - Nutritional monitoring appointment - nutritionist

  1. Evaluate adherence to the eating plan.
  2. Offer nutritional treatment according to the assigned intervention group.
  3. Schedule in 30 days for your next nutritional appointment.
  4. Make an appointment a few days before your next nutritional appointment to perform blood and urine lab tests.

month 2 - Full Assessment Nutritional Appointment - Nutritionist

  1. Perform an evaluation of nutritional status, quality of life and body composition.
  2. Offer nutritional treatment according to the assigned intervention group.
  3. Schedule in 30 days for your next nutritional appointment.

month 3 - Nutritional monitoring appointment - nutritionist

  1. Evaluate adherence to the eating plan.
  2. Offer nutritional treatment according to the assigned intervention group.
  3. Schedule in 30 days for your next nutritional appointment. 4.3 - Nutritional monitoring appointment - nutritionist

5.Evaluate adherence to the eating plan. 6.Offer nutritional treatment according to the assigned intervention group. 7.Schedule in 30 days for your next nutritional appointment. 7.1Schedule a few days before your nutritional appointment for blood and urine lab tests.

month 4 - Full Assessment Nutritional Appointment - Nutritionist

  1. Perform an evaluation of nutritional status, quality of life and body composition.
  2. Offer nutritional treatment according to the assigned intervention group.

SAMPLE SIZE: 50 participants

STATISTIC ANALYSIS:

For the comparison of proportions between the groups, it will be done with X2 or Fisher's exact test and to compare quantitative variables, Student's T or Mann-Whitney U will be used. For the intra-group comparisons, Mc Nemar will be used for the qualitative variables and Anova for repeated samples or Friedman's Anova for the quantitative variables. For the analysis of the interaction or intervening variables, a stratified statistical analysis will be carried out, using contingency tables and the Mantel-Haenszel method. The results will be considered statistically significant if the value of p \<0.05.

03

Conditions studied

  • Chronic Kidney Diseases
  • Protein-Energy Malnutrition

Keywords

  • chronic kidney disease
  • PEW
  • nutrition
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age
  • Patients with diabetic kidney with \<60 ml / min / 1.73m2 and ≥15 ml / min / 1.73m2, (stage G3a, G3b and G4 respectively)
  • Patients with protein energy expenditure (defined by serum albumin \< 3.8 g/dl)
  • Patients with protein energy expenditure (defined by 24-hour recall less than a dietary protein intake \<0.6 g/kg/d or have a consumption \<25 kcal/kg/d
  • Patients who can read and write (or primary caregiver)
  • Domicile within the metropolitan area

Exclusion criteria

Exclusion Criteria:

  • Previous hospitalizations in the last month
  • Patients with serious complications (chronic infection, septicemia, cancer, , Alzheimer's, uncontrolled heart failure, liver failure, cerebrovascular syndrome, malabsorption syndrome, or allergy to any ingredient in the nutritional supplement)
  • Patients with actual consumption of food supplements and / or keto analogues.

Elimination Criteria:

  • Failure to attend nutritional assessment and biochemical testing at baseline, 2 months, and end of the study.
  • Failure to take the supplement >10% (>12 failed doses).
  • Diagnosis of any comorbidity during the intervention period.
  • Initiation of replacement therapy.
  • Identification of adverse effects.
  • Withdrawal of voluntary participation by the patient.
  • Death.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Single (Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Arm Intervention

    Intervention group: The specialized oral supplement is provided, with the consumption of 1 serving (70g-dissolved in 237 ml natural water) per day in conjunction with individualized nutritional counseling. For 4 months

    Dietary Supplement: Nutritious Shake

  • Other
    Arm no Intervention

    Control group: They receive specialized nutrition considering the recommendations of the clinical practice guidelines for CKD. For 4 months

    Behavioral: Nutritional counseling

Interventions

  • Dietary supplementNutritious Shake

    Powder 70 g/d diluted in 237 ml natural water

    Also known as: NIN

  • BehavioralNutritional counseling

    Specialized nutritional recommendations for CKD

06

What researchers measure

Primary outcomes

  1. Serum Albumin (g/dl)

    Changes in serum albumin (g/dl) for all the patients at baseline and month 4.

    Time frame: baseline intervention and 4 months

  2. Dietary intake (kcal/kg/day)

    Changes in dietary caloric intake of patients at baseline and month 4.

    Time frame: baseline intervention and 4 months

Secondary outcomes

  1. Adherence to nutritional treatment

    Number of patients who manage to adhere correctly to the treatment, applying a Likert scale.

    Time frame: baseline intervention and 4 months

  2. Adverse effects

    Number of patients who present adverse effects during the intervention, considering frequency and intensity by applying SAS (symptom assessment scale) and Bristol Scale.

    Time frame: baseline intervention and 4 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Carrero JJ, Stenvinkel P, Cuppari L, Ikizler TA, Kalantar-Zadeh K, Kaysen G, Mitch WE, Price SR, Wanner C, Wang AY, ter Wee P, Franch HA. Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr. 2013 Mar;23(2):77-90. doi: 10.1053/j.jrn.2013.01.001. PubMed 23428357 ↗
  • Riella MC. Nutritional evaluation of patients receiving dialysis for the management of protein-energy wasting: what is old and what is new? J Ren Nutr. 2013 May;23(3):195-8. doi: 10.1053/j.jrn.2013.01.023. PubMed 23611546 ↗
  • Perez-Torres A, Gonzalez Garcia ME, San Jose-Valiente B, Bajo Rubio MA, Celadilla Diez O, Lopez-Sobaler AM, Selgas R. Protein-energy wasting syndrome in advanced chronic kidney disease: prevalence and specific clinical characteristics. Nefrologia (Engl Ed). 2018 Mar-Apr;38(2):141-151. doi: 10.1016/j.nefro.2017.06.004. Epub 2017 Jul 26. English, Spanish. PubMed 28755901 ↗
  • Kovesdy CP, Kopple JD, Kalantar-Zadeh K. Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: reconciling low protein intake with nutritional therapy. Am J Clin Nutr. 2013 Jun;97(6):1163-77. doi: 10.3945/ajcn.112.036418. Epub 2013 May 1. PubMed 23636234 ↗
  • Zhang X, Bansal N, Go AS, Hsu CY. Gastrointestinal symptoms, inflammation and hypoalbuminemia in chronic kidney disease patients: a cross-sectional study. BMC Nephrol. 2015 Dec 11;16:211. doi: 10.1186/s12882-015-0209-z. PubMed 26651991 ↗
  • Paes-Barreto JG, Silva MI, Qureshi AR, Bregman R, Cervante VF, Carrero JJ, Avesani CM. Can renal nutrition education improve adherence to a low-protein diet in patients with stages 3 to 5 chronic kidney disease? J Ren Nutr. 2013 May;23(3):164-71. doi: 10.1053/j.jrn.2012.10.004. Epub 2012 Nov 27. PubMed 23194841 ↗
  • Tomayko EJ, Kistler BM, Fitschen PJ, Wilund KR. Intradialytic protein supplementation reduces inflammation and improves physical function in maintenance hemodialysis patients. J Ren Nutr. 2015 May;25(3):276-83. doi: 10.1053/j.jrn.2014.10.005. Epub 2014 Nov 25. PubMed 25455421 ↗
  • Kalantar-Zadeh K, Cano NJ, Budde K, Chazot C, Kovesdy CP, Mak RH, Mehrotra R, Raj DS, Sehgal AR, Stenvinkel P, Ikizler TA. Diets and enteral supplements for improving outcomes in chronic kidney disease. Nat Rev Nephrol. 2011 May 31;7(7):369-84. doi: 10.1038/nrneph.2011.60. PubMed 21629229 ↗
  • Cheu C, Pearson J, Dahlerus C, Lantz B, Chowdhury T, Sauer PF, Farrell RE, Port FK, Ramirez SP. Association between oral nutritional supplementation and clinical outcomes among patients with ESRD. Clin J Am Soc Nephrol. 2013 Jan;8(1):100-7. doi: 10.2215/CJN.13091211. Epub 2012 Oct 18. PubMed 23085729 ↗
  • Satirapoj B, Prapakorn J, Punpanich D, Pongsuparbchon C, Supasyndh O. The effect of ONCE Renal on minerals and electrolytes in predialysis patients with chronic kidney disease. Int J Nephrol Renovasc Dis. 2016 Apr 5;9:81-6. doi: 10.2147/IJNRD.S98179. eCollection 2016. PubMed 27103839 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2018 (actual). Primary completion is estimated for Feb 2025, 79 months after the start.

Of 40 industry-sponsored interventional studies with no phase under Renal Insufficiency, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 79 months is above that.

Counting every sponsor, half of 620 studies reached it within 23 months; a quarter within 10 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Aug 28, 2024
StartActual
Jul 10, 2018
Primary completionEst.
Feb 2025
CompletionEst.
Mar 2025
Last update
Dec 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06576479
Lead sponsor
NIN Institute
Collaborators
Hospital Civil de Guadalajara
Responsible party
Ari Cisneros-Hernández (Investigador Principal, Hospital Civil de Guadalajara) — Principal investigator
First posted
Aug 28, 2024
Start date
Jul 10, 2018
Primary completion
Feb 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
Dec 18, 2024

Study contacts

Paola Azucena Alvarado Pelayo, Bachelor
Contact
paola.alvarado@nin.com.mx
011 52 3320587471
Ari Cisneros Hernández, Master
Contact
aricisneroshernandez@gmail.com.mx
011 52 3335762299
Paola Azucena Alvarado Pelayo, Bachelor
principal investigator · Hospital Civil Fray Antonio Alcalde

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion